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Abstract
Background: Raf kinase inhibitory protein (RKIP), also known as phoshaptidylethanolamine binding protein (PEBP), has
been shown to inhibit Raf and thereby negatively regulate growth factor signaling by the Raf/MAP kinase pathway. RKIP has
also been shown to suppress metastasis. We have previously demonstrated that RKIP/Raf interaction is regulated by two
mechanisms: phosphorylation of RKIP at Ser-153, and occupation of RKIP’s conserved ligand binding domain with a
phospholipid (2-dihexanoyl-sn-glycero-3-phosphoethanolamine; DHPE). In addition to phospholipids, other ligands have
been reported to bind this domain; however their binding properties remain uncharacterized.
Methods/Findings: In this study, we used high-resolution heteronuclear NMR spectroscopy to screen a chemical library and
assay a number of potential RKIP ligands for binding to the protein. Surprisingly, many compounds previously postulated as
RKIP ligands showed no detectable binding in near-physiological solution conditions even at millimolar concentrations. In
contrast, we found three novel ligands for RKIP that specifically bind to the RKIP pocket. Interestingly, unlike the
phospholipid, DHPE, these newly identified ligands did not affect RKIP binding to Raf-1 or RKIP phosphorylation. One out of
the three ligands displayed off target biological effects, impairing EGF-induced MAPK and metabolic activity.
Conclusions/Significance: This work defines the binding properties of RKIP ligands under near physiological conditions,
establishing RKIP’s affinity for hydrophobic ligands and the importance of bulky aliphatic chains for inhibiting its function.
The common structural elements of these compounds defines a minimal requirement for RKIP binding and thus they can be
used as lead compounds for future design of RKIP ligands with therapeutic potential.
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Introduction
The Raf-1 kinase inhibitory protein (RKIP) serves as a regulator
of the MAP kinase signal transduction cascade through its
interaction and inhibition of Raf-1 kinase activity [1,2]. Phos-
phorylation of RKIP at Serine-153 by protein kinase C abolishes
RKIP’s inhibition of Raf-1 [3] and converts it to an inhibitor of
the G-protein coupled receptor kinase, GRK-2, thus facilitating
cross-talk between the EGF and GPCR signaling pathways [4].
Furthermore, RKIP functions as a metastatic tumor suppressor in
prostate [5] and breast cancers [6], sensitizes human prostate and
breast cancer cells to drug induced apoptosis and regulates the
integrity of the cell cycle via the spindle checkpoint [7,8] (reviewed
in [9]). These reports highlight the significance of RKIP in
mammalian cells as a vital regulator of mitosis, cell differentiation
and apoptosis.
Long before its function as a kinase inhibitor was identified,
RKIP was isolated from the soluble fraction of bovine brain
extracts through affinity chromatography to an immobilized dye
(Cibacron Blue) [10]. This dye is generally considered a nucleotide
analog, and thus the affinity of RKIP to the dye suggested a
nucleotide-binding function for RKIP. In addition, gel filtration
and lipid affinity chromatography were used to demonstrate
binding of a number of organic anions, steroids and also the lipid
membrane component, phosphatidylethanolamine [10,11]. Con-
sequently, RKIP was originally named PEBP for its function as a
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10479phosphatidylethanolamine binding protein. Subsequent studies
demonstrated that RKIP binds only negatively charged phospha-
tidylglycerol in liposomes and lipid monolayers [12]. The
macroscopic methods used in these previous studies did not
identify the specific binding site(s) for these interactions nor
determine site-specific affinity of these ligands to RKIP. Also the
effective concentrations of ligands in these methods are very high,
and consequently they can detect weak binding events that may
not be physiologically relevant.
Amino acid sequence analysis of RKIP has identified it as a
member of a large protein family named the PEBP family. This
family has homologs present from bacteria to mammals
[13,14,15,16]. Among the mammalian members of this family,
the pocket region between residues 63 and 126 (based on the
bovine RKIP numbering scheme [17]) displays a particularly high
level of sequence identity [18], suggesting a conserved function for
this region. The structures of RKIP and its homologs from a
number of species have been determined using x-ray crystallog-
raphy [17,19,20,21,22,23]. These crystal structures reveal a
globular protein with a beta-sheet core and a prominent solvent
exposed pocket. The residues that form the pocket are among the
aforementioned highly conserved residues. In three of the five x-
ray structures of mammalian RKIP proteins a small ionic ligand is
bound in this pocket [17,19], confirming this pocket as a ligand-
binding site. While two of these three structures (Protein Data
Bank entries 1A44 and 1BEH) contain a small ion from the buffer
as the ligand, the third (PDB id 1B7A) contains O-phosphor-
ylethanolamine (PE), the soluble polar head group of the
membrane phospholipid phosphatidylethanolamine. The RKIP-
PE complex is the only crystal-based structural evidence to date for
the binding of an organic ion to the pocket. Although PE is a
phospholipid head group and the crystal structure may represent
the mode of phospholipid–RKIP interaction, this interpretation is
still speculative because PE lacks the diacylglycerol moiety that
constitutes the majority of the phospholipids. Moreover, the
crystals of RKIP with PE bound were formed at pH 4.6 in the
presence of 100 mM PE [17], and the other crystal structures of
mammalian RKIP with ligands bound to the pocket were also
determined at low pH (# pH 5.5). Thus, little is known about the
mode(s) of RKIP-ligand interactions under near physiological
solution conditions.
Although the previous studies have reported a number of RKIP
ligands, they collectively lack definitive data regarding binding
affinity, the location of the binding site(s) as well as the ligand
specificity of RKIP in solution under near physiological condi-
tions. The chemical diversity of the previously identified ligands
raises fundamental questions about the structural basis for RKIP–
ligand interactions: Does the pocket have an extremely broad
binding specificity so that it can bind to all of these ligands? If so,
what is the chemical space for the pocket ligand? Or alternatively,
does RKIP have another binding site distinct from the pocket? To
address these questions it is necessary to investigate ligand binding
by a method that permits quantitative and structural analysis of
protein-ligand interactions under near physiological solution
conditions.
Solution NMR spectroscopy meets the above criteria for high-
resolution and quantitative analysis of protein-ligand interactions.
Ligand binding experiments using NMR spectroscopy require
relatively low protein concentrations and thus allow for flexibility
in the choice of solution conditions. In addition, it has the ability to
detect weak interactions and to map specific protein residues
affected by ligand binding. These attributes make NMR
spectroscopy an ideal tool to perform a comprehensive analysis
of the ligand binding properties of RKIP, which was not possible
with the previously implemented techniques. Furthermore, it can
also determine the site-specific affinity of the interactions [24]
providing a significant advantage over the methods previously
used to study RKIP-ligand interactions. We have reported the
sequence specific resonance assignments of RKIP at pH 7.4 [25],
the prerequisite for NMR-based structural analysis [26], providing
the foundation for detailed characterization of RKIP-ligand
interactions by NMR spectroscopy. Recently, we characterized
the binding of locostatin, a putative RKIP inhibitor, to the RKIP
pocket [27].
In this study, we used NMR-based screening to assay
interactions of RKIP with a number of potential ligands by
NMR spectroscopy. Surprisingly, the binding of many com-
pounds previously postulated or reported to interact with RKIP
was not detectable at near physiological solution conditions even
at millimolar concentrations of the compounds. In contrast, we
discover three novel ligands for RKIP, and we provide evidence
for site-specific binding of these compounds to the pocket and
their binding affinity. In addition, we examined the biological
effect of these compounds and identified one that had off target
effects which reduced MAPK activity. Taken together, this work
defines the ligand-binding properties of RKIP and suggest its
potential role as a scavenger for hydrophobic compounds within
cells.
Results
NMR assay of ligand binding to RKIP
To investigate whether potential non-lipid ligands reported in
the literature actually bind to RKIP and, if so, to define their
binding site, we tested the interactions between RKIP and these
compounds using NMR spectroscopy [21,25]. By comparing the
1H,
15N-heteronuclear single-quantum correlation (HSQC) spectra
of
15N-labeled rat RKIP (rRKIP) in the presence and absence of a
potential ligand, we can detect ligand binding as perturbations to
the NMR cross peaks (referred to as ‘‘chemical shift perturbations’’
hereafter) [24]. Note that only the backbone and side chain amide
moieties of the
15N-rRKIP give rise to NMR signals while an
unlabeled ligand is spectroscopically silent. The recently complet-
ed sequence-specific NMR assignments for rRKIP [25] allow us to
identify the residues affected by ligand binding and thus to map
the binding site.
Non-lipid molecules assayed for binding included: O-phosphor-
ylethanolamine (PE), the head group of phosphatidylethanol-
amine; the nucleotides GDP, GTP and cAMP; the phosphorylated
amino acids O-phosphorylserine, O-phosphorylthreonine and O-
phosphoryltyrosine; tryptophan, phenylalanine and inorganic
phosphate (Pi)( Table S1). Surprisingly, under the near physio-
logical solution conditions used (pH 7.4, 100 mM NaCl, 30uC),
none of these non-lipid compounds caused significant chemical
shift perturbations for the rRKIP residues, even at very high ligand
concentrations used (Table S1 and Figure S1). This suggests the
importance of examining ligand binding to RKIP in solution
under near-physiological conditions. In contrast, a previously
identified RKIP ligand, DHPE, caused large perturbations
(Figure 1D). Interestingly, although PE had previously been co-
crystallized with bovine RKIP at low pH [17], it did not interact
with the protein under these more physiological conditions
(Figure 1A and C). Together, these results indicate that rRKIP
has very weak affinity, if any, to these compounds.
Effects of pH on RKIP structure
An apparent conundrum in this study is the lack of binding of
PE to rat RKIP in solution despite the successful crystallization of
Identification of RKIP Ligands
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proteins are highly homologous, particularly among the residues
forming the pocket, it is unlikely that these proteins have distinctly
different ligand-binding properties. The RKIP/PE complex was
crystallized at pH 4.6, which is much lower than the pH used in
our solution studies (pH 7.4). The pocket contains a conserved His
residue (His-85 in the bovine RKIP numbering), and the pKa of
His is typically between 6.0-7.0 [28]. These observations led us to
hypothesize that pH may affect the structure and function of the
RKIP pocket. To investigate the effect of pH, we performed pH
titration of RKIP monitoring the amide proton chemical shifts
with the
15N-HSQC spectrum.
Figure 1. Overlay of
1H,
15N-HSQC spectra of RKIP in the absence (black) and presence (red) of a potential ligand. (A) PE (10 mM) does
not result in any significant chemical shift perturbations. (B)
1H,
15N-HSQC spectra of RKIP taken at pH 6.0 (red) and at pH 7.4 (black) showing a large
number of missing peaks at pH 6.0. In all the panels, red contours are plotted over black contours, and thus a black cross peak appears only when its
corresponding peak drawn in red is either shifted or missing. RKIP chemical shift perturbations for amide proton resonances by PE (10 mM) (C) or
DHPE (4.5 mM) (D) at pH 7.4 plotted as a function of residue number. Secondary structural elements are depicted at the top with beta-sheet and
alpha-helices represented by closed and open boxes, respectively. Gray boxes indicate the position of residues that form the ligand-binding pocket.
(E) RKIP chemical shift perturbations by PE (100 mM) at pH 6.0. Note that panel E is plotted on a smaller vertical scale than that for C and D.
doi:10.1371/journal.pone.0010479.g001
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exhibited a dramatic loss in peak intensity (Figure 1B), characteristic
of an increase in motion on the ms-ms timescale [26]. These peaks
were mapped to residues in the loops that form the binding pocket.
Because of the peak intensity decrease, we could not accurately
determine the pKa values for these residues, which prevented us from
identifying the origin of the pH-induced structural perturbations in
the pocket region. Nevertheless, these results clearly indicate that the
pocket conformation and/or dynamics are sensitive to pH change
and that these loop regions are able to sample multiple conformations
while rRKIP retains the overall, folded conformation.
There were other HSQC peaks that exhibited significant pH-
dependent migration but no significant decrease in intensity. We
were able to determine the pKa value for 46 residues of this class.
We did not find a clear clustering pattern in the distribution of
residues with similar pKa values, except for two discrete sites distal
to the conserved pocket corresponding to regions adjacent to
solvent exposed histidines at positions 23 and 159 (data not
shown). Moreover, the residues near His-23 and -159 do not
exhibit ligand-induced chemical shift perturbations at pH 7.4,
suggesting that these sites and the pocket are structurally
independent and pH-dependent structural changes at these sites
do not affect ligand binding to the conserved pocket.
Effects of pH on ligand binding by RKIP
The above results suggest that an increased flexibility at lower
pH might alter the ligand-binding properties of RKIP. To
investigate the effect of lower pH on ligand binding, a number
of ligands tested at pH 7.4 were reexamined for binding to RKIP
at pH 6.0. This pH value was chosen because below this pH value
we observed a significant loss of spectral quality. In the presence of
PE and O-phosphoryltyrosine at pH 6.0, a number of residues in
the loops surrounding the ligand pocket of RKIP displayed
significant broadening of amide proton peaks in the HSQC
spectra. However, chemical shift perturbations for pocket residues
were very small, only slightly above background in these spectra
(Figure 1E), much smaller than those observed for phospholipid
compounds (Figure 1D). These results suggest that PE and O-
phosphoryltyrosine have very low affinity for RKIP at this pH.
The phosphate group of PE has a reported pKa of ,5.8,
suggesting that the affinity of PE may be much higher at lower pH
than at 6.0. However, due to the limitations discussed above, we
were not able to investigate this possibility. Our data suggests that
the presence of PE in the crystal structure of bovine RKIP (PDB
id: 1b7a) may be a product of the weak affinity of PE at low pH
coupled with its high concentrations used during crystallization.
Two of the four compounds exhibiting binding at pH 7.4,
DHPG and DHPS, demonstrated similar patterns of chemical
shift perturbations at pH 6.0 as previously described [21].
Titration of the phospholipids at pH 6.0 confirmed interactions
with similar affinity for DHPG and DHPS to that observed at
pH 7.4 (Table S1). In contrast, while PA binding at pH 6.0
perturbed a similar subset of residues as it did at pH 7.4, the
trajectory of the peak shifts was different. As PA was titrated in, the
HSQC peaks did not change their positions but their intensities
decreased, and a new set of peaks appeared (Figure 2A). This
behavior is characteristic of slow interconversion between the free
and ligand-bound states [26]. Furthermore, the affinity of PA for
RKIP was at least 3-fold higher at pH 6.0 than at pH 7.4
(Figure 2B). The mono-substituted phosphate moiety of PA has a
pKa of 8.0 [29] indicating that its protonation state is sensitive to
changes in pH between pH 7.4 and pH 6.0. In comparison, the
pKa values of the other phospholipids examined in this study are
expected to be much lower, as the pKa of the phosphate group of
dimyristoyl-phosphatidylethanolamine has been calculated to be
,1.7 [29]. The remarkable similarities between the peak shift
patterns observed for DHPE, DHPG and DHPS at pH 6.0 and
pH 7.4 are in stark contrast with the differences seen for PA
binding at the two pH values, suggesting that the higher affinity for
PA at pH 6.0 results from the protonation of the ligand and not
from a pH-dependent effect on the RKIP binding pocket itself.
Together, these results suggest that the compounds that showed no
significant binding in our NMR assays (Table S1) have very weak
affinity at best to RKIP in near physiological pH range.
NMR-based chemical library screen reveals three novel
RKIP ligands
The failure of previously reported compounds, except for the
short-chain lipid, to bind RKIP at physiological pH has revised
our understanding of RKIP’s ligand binding properties. RKIP is
Figure 2. A portion of RKIP HSQC spectra illustrating the difference in the DHPA-induced chemical shift perturbations of residue
182 at pH 7.4 and 6.0. (A) DHPA titration at pH 7.4 causes the peak to continuously shift, characteristic of fast exchange kinetics. (B) Titration at
pH 6.0 causes the peak intensity to decrease with a concomitant appearance of a new peak, characteristic of slow exchange kinetics. The arrows
indicate the trajectories of cross peak movements. Panel (A) shows data with DHPA concentrations of 0, 0.05 0.25, 0.5, 1.0, 2.5 and 7.5 mM, and (B)
data with 0, 0.05, 0.25, 0.5, 1.0, 2.5 and 4.5 mM DHPA.
doi:10.1371/journal.pone.0010479.g002
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order to better define the chemical space of RKIP ligands and also
to discover lead compounds for RKIP inhibitors, we have
performed NMR-based screening. We utilized the chemical shift
perturbation method described above and screened approximately
6, 000 compounds from a commercially available library of ‘‘drug-
like’’ small organic chemical compounds.
We have identified three compounds: N’-(2,4-dinitrophenyl)-
2,3,4,5,6-pentafluorobenzohydrazide (compound 26), N-{[(2-
bromo-4-nitrophenyl)amino]carbonothioyl}-3-(2-thienyl)acryla-
mide (compound 48) and 4-({4-[(2,4-dinitrophenyl)amino]phe-
nyl}amino)-4-oxo-2-butenoic acid (compound 98)( Figure 3A).
These compounds caused unambiguous NMR chemical shift
perturbation (Figure 3A). The three compounds affected very
Figure 3. Newly identified RKIP ligands. (A) The chemical structures of compounds 26, 48 and 98 and their effects on the RKIP HSQC NMR
spectrum. The
1H,
15N HSQC spectrum of RKIP taken in the presence of the indicated compound is plotted in red and a control spectrum in the
absence of a compound in black. The black spectrum is plotted over the red one so that red cross peaks are visible only for those that are perturbed
by the compound (B) A cartoon representation of the crystal structure of RKIP bound to PE (left; PDB id, 2IQX), and the locations of residues whose
HSQC peaks were perturbed by compound 26. Red, yellow and white spheres indicate the Ca positions for residues whose peaks were shifted by
more than two peak widths, 1 to 2 peak withs and less than one peak width, respectively. Because the three compounds perturbed very similar sets
of residues, only data for compound 26 are shown.
doi:10.1371/journal.pone.0010479.g003
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binding. Most of the HSQC peaks affected by these compounds
were mapped to residues surrounding the pocket (Figure 3B),
indicating that the pocket is a preferred binding site for RKIP
ligands and RKIP does bind to small organic compounds that
are chemically distinct from lipids (Figure 3B). The three
compounds include either 2,4-dinitrophynyl amine or 2-bromo-
4-nitrophynyl amine moieties (Figure 3A), suggesting that the
4-nitrophenyl group serves as a common element recognized by
RKIP. Among the screened compounds, there were a total of 19
others containing either 2,4-dinitrophynyl amine or 2-bromo-4-
nitrophynyl amine moieties that exhibited no sign of RKIP
binding, suggesting that the substituted nitrophenyl amine
groups are not sufficient for RKIP binding.
Newly identified compounds have no effect on
RKIP-Raf-1 interaction and RKIP phosphorylation
In our previous studies, we have shown that RKIP pocket
occupancy by the short-chain lipid, DHPE, causes dissociation of
RKIP from Raf-1 [21]. In contrast, we observed that locostatin,
which also bound to the RKIP pocket, had no effect on RKIP-
Raf-1 interaction [27]; we have attributed locostatin’s inability to
perturb RKIP function to its smaller size than DHPE. The size of
the three identified compounds is similar to that of locostatin and
also had no effect on Raf-1 interaction (Figure 4A). Furthermore,
we monitored RKIP phosphorylation by PKC in the presence of
the three compounds and used DHPE as a control. In the presence
of DHPE, as previously shown, RKIP phosphorylation was
reduced in a dose dependent manner (Figure 4B). By contrast,
as observed with locostatin, increasing concentrations of these
compounds (up to 2.5 mM) had no effect on RKIP phosphory-
lation by PKC (Figure 4B).
Compound 48 impairs EGF-induced MAPK in HeLa cells
We have previously shown that EGF-induced MAPK activity is
augmented in HeLa cells depleted of RKIP [1]. If RKIP binding
to Raf-1 requires pocket binding, then compounds that bind the
RKIP pocket would interfere with downstream signaling to
MAPK. However, we showed that locostatin binds to the RKIP
pocket with no effect on Raf-1 association nor RKIP phosphor-
ylation by PKC and did not change the EGF-induced MAPK
activity in HeLa cells in the presence or absence of RKIP [27].
Similarly, two of the compounds (98 and 26) from our screen
mimicked the lack of effect by locostatin on EGF-induced MAPK
activity (Figure 5). In addition, we observed compound 48 at
20 mM had no effect on wild-type HeLa cells; however compound
48 reduced MAPK activity by 34611% (mean 6 SEM, n=3) in
RKIP depleted cells (Figure 5). To further examine the effect of
compound 48, we compared the dose response of compound 26 as
a control to that of compound 48 (Figure 6 and 7). As predicted,
compound 26 at all concentrations tested had no effect on EGF-
induced MAPK activity in HeLa cells in the presence or absence
of RKIP (Figure 6). In contrast, the inhibitory effect was dose-
dependent for compound 48 with respect to RKIP depleted cells
but dose-independent in wild-type RKIP cells (compare
Figure 7A with 7B).
Compound 48 reduced cell viability in HeLa cells
To examine the effect of these compounds on HeLa cells, we
assayed cell viability as assessed by metabolic activity in the
presence or absence of the compounds from the screen. All
compounds examined with the exception of compound 48 had no
effect on cell viability. In contrast, compound 48 reduced cell
viability by 4366 and 3466% in wild-type and RKIP depleted
cells respectively (mean 6 SEM; n=4; Figure 8). In contrast to
the viability assays, MAP kinase assays are assessed after shorter
exposure to the drug which may account for the differential
response to compound 48 between RKIP-expressing and RKIP-
depleted cells observed in the MAP kinase assay. Taken together,
these results suggest that compound 48 is toxic at 20 mM and may
result in off target effects.
Discussion
Despite a number of investigations into the ligand binding
properties of RKIP, there has remained a lack of detailed
quantitative and structural analysis of ligand binding in solution.
In this study, we used NMR spectroscopy to address a number of
fundamental questions raised by the diversity of ligands reported
to bind RKIP and to provide definitive quantitative structural data
regarding the ligand specificity of RKIP. Through this effort we
provide the first comprehensive structural analysis of ligand
binding to the conserved pocket of RKIP in solution.
We also found significant pH-dependent changes of HSQC
peak intensity for residues surrounding the pocket. Although the
loss in peak intensity precluded detailed analysis, these results are
indicative of changes in the conformation and/or dynamic
properties of the region at lower pH. We found evidence for
weak binding of PE at pH 6.0. Likewise, the affinity of PA was
higher at pH 6.0 relative to that at pH 7.4. However, lowered pH
does not alter the binding of DHPE, DHPG and DHPS, strongly
suggesting that the pocket is unaffected by pH change over this
range. The difference in the binding affinity of PA between the
two pH values can be explained by a change in the protonation
state of the phosphate group of PA, suggesting that the
microenvironment of the cell will determine the localized effect
of ligand binding as well as protein-protein interaction. RKIP
binds more strongly to the di-anionic form than the mono-anionic
form of the phosphate group. It is, however, possible that a further
decrease in pH, particularly in the range near the pKa of
carboxylates (4–4.5) may induce substantial changes in the RKIP
pocket structure and its ligand-binding properties. Also in this
study, we observed that there are conserved His residues that are
sensitive to pH which suggests that they may be involved in
localized protein-protein interaction and are not involved in ligand
binding.
While prior structural information regarding binding of ligands
to the conserved pocket of RKIP was limited to crystal structures
that contained only small anions [17,19], this work significantly
expands our knowledge of the chemical space for RKIP ligands
and demonstrates a definitive specificity for phospholipids under
near physiological conditions. The binding analysis of a drug-like
compound, locostatin [30], its precursors and their stereoisomers
revealed that the RKIP pocket can also bind to non-lipid
compounds with a certain level of stereospecificity [27]. The
RKIP ligands identified in this work all bound to the conserved
pocket, and no other binding sites were found. These observations
strongly suggest that the pocket is the main, if not the only, binding
site in RKIP for organic compounds.
These initial studies lead to screening for compounds that had a
similar structure as the non-lipids described in Table S1.
Essentially these were planar hydrophobic compounds that, unlike
locostatin, were not capable of chemical cross-linking, which made
them easily studied by NMR. These compounds bound to the
pocket with an affinity similar to locostatin; however, their side
chains allowed for binding to different regions within the RKIP
binding pocket.
Identification of RKIP Ligands
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affected RKIP function via pocket binding. From this study we
established that these compounds, even up to millimolar
concentrations did not affect RKIP association with Raf-1 and
did not alter Ser-153 phosphorylation by PKC. These results
confirm and extend previous findings that locostatin can similarly
bind the RKIP pocket without altering association with Raf-1 or
kinases such as PKC. Based on these findings, we postulated that
MAPK should not be affected by drug binding. However, one out
of the three compounds (compound 48) displayed off target effects
by reducing MAPK activity as well as metabolic activity in HeLa
cells. This effect was more pronounced in RKIP depleted cells
suggesting a transient protective role for RKIP with respect to
MAPK activation, against toxic drugs as previously observed for
locostatin.
In this study, we describe the importance of the microenviron-
ment with respect to pH for ligand binding to the RKIP pocket.
The observation that bulky lipids such as DHPE inhibit both Raf-1
and kinase association with RKIP suggests that interaction with
residues in the vicinity of the pocket rather than binding within the
Figure 4. DHPE but not compounds 98, 48, 26 nor locostatin decreases RKIP interactions with Raf-1 and PKC. (A) Representative
western blot of RKIP association with Raf-1 in the presence of 1.5 mM Compounds 26, 48 or 98 as well as locostatin or DHPE. (B)P K C
phosphorylation of RKIP in the presence of increasing concentrations of DHPE or compounds 98, 48,o r26 (Representative autoradiogram is
shown).
doi:10.1371/journal.pone.0010479.g004
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identified three compounds that bind to the RKIP binding pocket
with no effect on Raf-1 association or RKIP phosphorylation. One
out of the three compounds from this screen (compound 48)
reduced MAPK activation in a dose dependent manner
independent of RKIP, suggesting off target effects. The structure
of these compounds which bind to RKIP should act as lead
compounds for future drug design which could ultimately lead to
intervention for diseases that develop from disregulation of the
pathways involving RKIP and/or its targets.
Figure 5. Compound 48 reduces EGF-induced MAPK activity. HeLa cells expressing wild-type or depleted RKIP were serum starved overnight
and then pre-treated for 30 min with 20 mM compounds (as indicated). EGF (10 ng/ml) was added in the final 5 minutes of incubation. (A) Whole cell
lysates (30 mg) were separated on SDS-PAGE gels (12.5%), transferred to nitrocellulose and analysed by immunoblotting with anti-phospho ERK (Top
panel: representative Western blot) and anti-total ERK antibodies (Bottom panel: representative Western blot). (B) ERK phosphorylation was assessed
by normalizing phospho-ERK levels to total ERK levels as depicted in bar graphs (Mean 6 SEM; n=3 independent experiments).
*p,0.05 indicates the
significance of change relative to the DMSO control in the presence of EGF.
doi:10.1371/journal.pone.0010479.g005
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PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10479Figure 6. Increasing doses of compound 26 does not change EGF-induced MAPK activity. HeLa cells expressing wild-type (A) or depleted
RKIP (B) were serum starved overnight and then pre-treated for 30 min with increasing doses of DMSO (control) or Compound 26. EGF (10 ng/ml)
was added in the final 5 minutes of incubation. Whole cell lysates (30 mg) were separated on SDS-PAGE gels (12.5%), transferred to nitrocellulose and
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Reagents and antibodies
A compound library containing 10, 000 drug-like chemicals was
purchased from ChemBridge. N’-(2,4-dinitrophenyl)-2,3,4,5,6-
pentafluorobenzohydrazide (compound 26), N- {[(2-bromo-4-
nitrophenyl)amino]carbonothioyl}-3-(2-thienyl)acrylamide (com-
pound 48), 4-{4-[(2,4-dinitrophenyl)amino]phenyl}amino)-4-oxo-
2-butenoic acid (compound 98) were from ChemBridge Corpo-
ration. (S)-(+)-4-benzyl-3-crotonyl-2-oxazolidinone (locostatin)
used for NMR analysis was from Aldrich. Protease inhibitor
cocktails and locostatin unless otherwise indicated were from
Calbiochem. All cell culture media and supplements were from
GIBCO (Invitrogen).
15N-ammonium chloride was from Cam-
bridge Isotope Laboratories. Anti-phospho and -total ERK
antibodies were from Cell Signaling Technology. Anti-rabbit
and –mouse IR dye secondary antibodies as well as Odyssey
blocking buffer used for Western blotting were purchased from LI-
COR Biosciences. Anti-RKIP antibody was developed as
described [3]. IgG sepharose beads were from Amersham
Biosciences (GE Healthcare). Biotinylated thrombin (50 U) was
from Novagen.
Cell lines and cell culture
HeLa cells stably expressing short hairpin RNA vectors for
depleting human RKIP or rat RKIP control (wild-type RKIP)
were maintained at 37uC/5% CO2 in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum,
50 U/ml penicillin and 50 mg/ml streptomycin under puromycin
(2 mg/ml) selection as previously described [1].
Protein expression
BL21(DE3) cells (Novagen) [31] harboring a pMCSG7-derived
expression vector [32] for rat RKIP were grown at 37uC in the M9
media with
15N-NH3Cl as the sole nitrogen source and supple-
mented with ampicillin (100 mg/ml). The expression construct
consisted of a His6 tag fused in frame with a TEV protease
cleavage signal and the entire open reading frame (residues 1-187)
of wild-type rat RKIP (rRKIP). Protein expression was induced
with 0.2 mM isopropyl-1-thio-b-d-galactoside (IPTG) when the
optical density at 600 nm of cultures reached ,0.7, and
expression was allowed to proceed for 16 hours at 30uC. The
His-tagged rRKIP expressing cells were harvested by centrifuga-
tion and stored at 280uC.
Protein purification
Cells having expressed His-tagged rRKIP were lysed in 50 mM
Tris-HCl pH 8.0 by a combination of hen egg lysozyme (0.5 mg/
ml) (Sigma) and sonication. The lysate was cleared by centrifu-
gation. Concentrated NaCl was added to the lysate at a final
concentration of 0.5 M. The solution was loaded onto a Ni-affinity
column (Ni Sepharose 6 Fast Flow; Amersham) equilibrated with
Column Wash Buffer (50 mM Tris-HCl pH 8.0, 500 mM NaCl).
The column was washed with 10 column volumes of Column
Wash Buffer followed by 5 column volumes of Column Wash
Buffer containing 20 mM imidazole. His-rRKIP was eluted from
the column with Column Wash Buffer containing 500 mM
imidazole. Fractions containing His-rRKIP were pooled, dialyzed
into 50 mM Tris-HCl pH 8.0, 250 mM NaCl, 1 mM DTT and
cleaved overnight with his-tagged TEV protease to remove the N-
terminal His6 tag by the protocol previously described [33]. The
cleaved protein was purified from the protease and the cleaved
affinity tag by passing the cleavage product over the nickel-affinity
column and collecting the column flow-through containing the
purified protein. Purity was found to be .95% by SDS-Page
analysis with yields routinely exceeding 50 mg/L of culture.
Samples for NMR analysis of ligand binding contained 75 mM
15N-rRKIP in 50 mM Tris-HCl pH 7.4 containing 100 mM
NaCl and 7% D2O. Ligand stocks were prepared in the same
buffer and the pH value adjusted appropriately.
NMR Spectroscopy
1H,
15N-HSQC spectra [34] of
15N-rRKIP in the presence of
the various ligands were acquired for 40 min at 30uC on a Varian
Inova 600 spectrometer equipped with a cryogenic probe and a 9-
position sample changer. NMR spectra were processed using the
NMRPipe suite [35]. Spectra were analyzed and peak list for apo
and ligand bound samples were generated using NMRView [36].
Exact peak positions and intensities were obtained using 2-
dimensional deconvolution of peak positions with the pkfit
program. Global fitting analysis of peak position and intensity
was performed using the program GLOVE (pkfit and GLOVE
were developed by the Peter E. Wright laboratory, The Scripps
Institute) modified to fit the data to a single-site binding model.
Errors were estimated through 500 Monte Carlo simulations of the
globally fitted data. The residue specific amide proton pKa values
were determined by fitting pH dependent changes of the amide
1H
chemical shifts to the Henderson-Hasselbach equation using
SigmaPlot 8.0 (Jandel Scientific).
Compound screening was performed in a two-step manner as
follows. In the first step, 2 ml each of 30 compounds (dissolved in
DMSO at the concentration of 5 mg/ml) were pooled and added
to 540 ml of 50 mM Tris-HCl pH 7.4 containing 100 mM NaCl,
7% D2O and 50 mM
15N-RKIP. The final concentration of each
compound (17 mg/ml) corresponds to 40–50 mM. The
1H,
15N-
HSQC spectra for RKIP with each pooled compound were
collected and compared with that of RKIP with DMSO (negative
control). The concentration (10%) of DMSO used in the initial
screen did not significantly alter the HSQC spectrum, indicating
that RKIP was stable in the presence of 10% DMSO. Hit
compounds were identified by individually analyzing each of the
compounds in those initial mixtures that gave significant HSQC
perturbation.
In vitro Raf kinase assay
The pRav-Flag-Raf-1 plasmid (TAP-Raf-1; Tandem Affinity
Purification using Protein A and Flag tagged-Raf-1) was
constructed as previously described [21] and stably expressed in
H19-7 cells. Briefly, TAP-Raf-1 was immunoprecipitated from
H19-7 cells that were serum starved overnight in DMEM media
with no supplements, and TAP-Raf was isolated on IgG sepharose
beads. Cells were lysed in TAP-lysis buffer (10 mM HEPES
pH 7.4, 3 mM MgCl2, 10 mM KCl, 5% Glycerol, 0.1% NP40)
and cleared by centrifugation. Cell lysates were combined with
pre-equilibrated TAP-lysis buffer IgG sepharose beads and
incubated for 1 h at 4uC. Beads were washed with TAP-lysis
buffer and equilibrated with binding buffer (10 mM HEPES
pH 7.4, 3 mM MgCl2, 10 mM KCl, 150 mM NaCl). Beads were
aliquoted and combined with RKIP (5 mg) and increasing
concentrations of RKIP binding compounds (98, 26 or 48),
analysed by immunoblotting with anti-phospho ERK and anti-total ERK antibodies. ERK phosphorylation was assessed by normalizing phospho-ERK
levels to total ERK levels as depicted in line graphs. The results shown are mean 6 range of two independent experiments.
doi:10.1371/journal.pone.0010479.g006
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6 cells/ml) expressing wild-type (A)o r
depleted RKIP (B) were serum starved overnight and then pre-treated for 30 min with increasing doses of DMSO (control) or compound 48. EGF
(10 ng/ml) was added in the final 5 minutes of incubation. Whole cell lysates (30 mg) were separated on SDS-PAGE gels (12.5%), transferred to
nitrocellulose and analysed by immunoblotting with anti-phospho ERK and anti-total ERK antibodies. ERK phosphorylation was assessed by
normalizing phospho-ERK levels to total ERK levels as depicted in line graphs. The results shown are mean 6 range of two independent experiments.
doi:10.1371/journal.pone.0010479.g007
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(DHPE) and incubated for 30 min at 4uC. Complexes were
washed three times with binding buffer with corresponding
concentrations of RKIP binding compounds (98, 26 or 48)o r
locostatin or DHPE and boiled in sample buffer (2X). Lysates were
separated on SDS-PAGE (12%), transferred to nitrocellulose and
immunoblotted with anti-RKIP antibody.
RKIP phosphorylation
In vitro phosphorylation of RKIP by PKCa was as previously
described [21]. Briefly, RKIP (5 mg) was combined with increasing
concentrations of RKIP binding compounds (98, 26 or 48),
locostatin or DHPE and the reaction was initiated with 100 mM
ATP containing 5 mCi of [c-
32P]ATP (Perkin Elmer) at 30uC for
10 min. The reaction was terminated using sample buffer (6X) and
boiling at 100uC for 5 min. Lysates were separated on SDS-PAGE
(12%), transferred to nitrocellulose and visualized by exposing to
film. Results were quantified using phospho-imager screens
(Molecular Dynamics) and analyzed with ImageQuant software [3].
MAPK activation assay
HeLa cells (wild-type or RKIP depleted) were seeded in 6-well
plates at 0.5610
6/ml and allowed to adhere overnight at 37uC [1].
Cells were serum starved overnight in DMEM media with no
supplements. The next day, cells were treated with 0.1% DMSO
(vehicle control), 20 mM locostatin or RKIP binding compounds (at
indicated concentrations) for 25 min followed by EGF (10 ng/ml)
for5 minat37uC.Thereactionwasterminated byplacing plates on
ice and washing with cold PBS (containing protease inhibitors).
Cells were homogenized by cell scraping in RIPA lysis buffer
supplemented with sodium orthovanadate (0.1 mM), sodium
fluoride (0.5 mM) and protease inhibitor mixture tablet. Cell lysates
were sheared five times in a 1 ml tuberculin syringe attached with a
21 G 619 mm needle, left on ice for 1 h and then spun at 16,
0006g for 15 minat 4uC. Celllysates (30 mg)wereresolved bySDS-
PAGE (12.5%), transferred to nitrocellulose and analysed by
Western blotting with anti-phospho ERK or anti-total ERK (Cell
Signaling Technology, Inc) primary antibodies. Membranes were
probed with anti-rabbitor –mouse IR dye secondary antibodies (LI-
COR Biosciences). The amount of MAPK activity determined for
each sample was normalized to total ERK in each sample. Digital
analysis of immunoreactivity was done using LI-COR Biosciences
Infrared Imaging System which is quantitative and independent of
exposure time. Odyssey software (version 2.1; Lincoln, NE) was
used for analysis of the immunoblots.
Cell Viability assay
Cell viability was determined as a measure of metabolic activity
according to manufacturer’s protocol with minor modifications.
Briefly, HeLa cells (wild-type or RKIP depleted) were seeded in
96-well plates at 4610
4/ml and allowed to adhere overnight at
37uC. The next day, cells were treated with 0.1% DMSO (vehicle
control) or 20 mM each of locostatin or RKIP binding compounds
for 30 min followed by 20 ml cell titer blue reagent resazurin
(Promega) for 2 h at 37uC. Metabolic activity was measured using
a fluorometer at 560Ex/590Em.
Statistical analysis
Differences between compound treated or untreated cells were
compared using a two-tailed unpaired Student’s t-test.
Supporting Information
Figure S1 Overlay of 1H, 15N-HSQC spectra of RKIP in the
absence (black) and presence (red) of a potential ligand that our
Figure 8. Compound 48 reduces cell viability in HeLa cells. HeLa cells (4610
4 cells/ml) expressing wild-type (open bars) or depleted RKIP
(solid bars) were serum starved overnight and then pre-treated for 30 min with 20 mM DMSO (control) or compound 48. Reaction was stopped by
the addition of cell titer blue (20 ml) to each well and incubated for 2 h at 37uC. Metabolic activity was measured on a fluorometer (Fluorescence
560Ex/590Em) and the results are described as the mean arbitrary units of fluorescence of triplicate wells of two independent experiments.
**p,0.01
indicates the significance of the change relative to the corresponding sample in the absence of compound 48.
doi:10.1371/journal.pone.0010479.g008
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PLoS ONE | www.plosone.org 12 May 2010 | Volume 5 | Issue 5 | e10479assay did not detect significant binding. The spectra are presented
in the same manner as in Fig. 1. Compounds tested are: (A) cAMP
(5 mM), (B) GTP (130 mM), (C) O-phosphorylserine (5 mM), (D)
O-phosphoryltyrosine (5 mM), (E) platelet activating factor
(13.8 mM). Their chemical structures are shown in Table 1. A
small number of cross peaks are affected in these spectra, but the
perturbations are due to a small change in the pH (less than 0.1
pH unit). This conclusion is confirmed by the spectrum (F), in
which the same set of peaks is affected by a small pH shift. Cross
peaks that are particularly sensitive to pH changes are enclosed in
blue boxes.
Found at: doi:10.1371/journal.pone.0010479.s001 (0.83 MB TIF)
Table S1 Summary of the NMR-based binding assays for
potential RKIP ligands.
Found at: doi:10.1371/journal.pone.0010479.s002 (0.22 MB
DOC)
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